Replacement therapy with parathyroid hormone (PTH) — the hormone found at low levels in patients with hypoparathyroidism — requires the presence of another hormone called fibroblast growth factor 23 (FGF23) to help the kidneys expel excess phosphate, a small study has found. The study, “PTH and FGF23 exert…
News
A retrospective study by the National Institutes of Health (NIH) suggests that healthcare costs for those with rare diseases have been underestimated, possibly being three to five times higher than for those without rare diseases. This study provides evidence of the potential effect rare diseases may have on public health…
The American Thyroid Association (ATA) diagnostic criteria for postoperative hypoparathyroidism are useful to doctors in grouping patients based on symptoms, which could help in managing the disease, a study reported. “However,” the researchers wrote, differentiating patients in this way “may underestimate the actual incidence,” or the number of…
AZP-3601, an investigational treatment for chronic hypoparathyroidism, was able to safely increase blood calcium levels in healthy volunteers in a Phase 1 clinical trial, top-line data show. “We are pleased with these clinical trial results for AZP-3601 … as they support a potential therapeutic profile that we believe can address…
A routine procedure called PGA — for parathyroid gland autotransplantation — often done following surgery to remove the thyroid gland, is associated with a higher risk of immediate hypoparathyroidism, a study shows. However, PGA did not raise the risk of permanent hypoparathyroidism, or that lasting more than six months.
Football and science seem to be disparate fields of play at first glance, but the nonprofit Uplifting Athletes is finding common ground by leveraging the popularity of college gridiron games to fund research for rare diseases. Its nearly two dozen chapters — representing college football teams across the nation…
Amolyt Pharma has raised $80 million in financing that will support the clinical development of AZP-3601, its experimental therapy for hypoparathyroidism. Hypoparathyroidism is caused by abnormally low levels of the parathyroid hormone (PTH), leading to low vitamin D and calcium levels, as well as high phosphorus levels…
In a woman whose severe hypoparathyroidism did not respond to standard treatment, constant infusion of a lab-engineered form of the parathyroid hormone (PTH) eliminated symptoms and improved her quality of life, a case study from Portugal reports. This medication, called Forsteo (teriparatide) and marketed in the U.S. as…
Four new mutations of the AIRE gene were identified for the first time in Chinese patients with autoimmune polyendocrine syndrome type 1 (APS1), a case series reports. The report also presents a thorough evaluation of the clinical and genetic characteristics of Chinese APS1 patients and some rarely observed symptoms.
Low levels of the parathyroid hormone (PTH) soon after a thyroidectomy is linked to a greater risk of chronic hypoparathyroidism, or that lasting more than six months, a study reported. Its findings suggest that blood tests to measure PTH levels may allow doctors to discharge sooner patients who are at low…
Recent Posts
- New weekly therapy moves toward Phase 3 for hypoparathyroidism
- My PATTH with hypoparathyroidism is unknown, but my purpose is clear
- As Tatum’s return from injury shows, a comeback is better than a setback
- Calcium, vitamin D supplements key after thyroid surgery, per study
- An at-home calcium tester is in development — and I’m celebrating!